Truxima, a monoclonal antibody (mAb), has been approved to treat adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non–Hodgkin’s lymphoma (NHL) as a single agent.
The post Teva, Celltrion get FDA nod for biosimilar to Roche’s cancer drug Rituxan appeared first on Pharmaceutical Business review.